Formulation and evaluation of dexlansoprazole controlled release tablets
Abstract
The aim of the present work is to formulate and evaluate controlled release of Dexlansoprazole matrix tablets used for treatment of gastroesophageal reflux disease (GERD). Development of CR Dexlansoprazole is proposed considering the adverse event profile and high fluctuation index of Dexlansoprazole observed with CR dosage forms. Dexlansoprazole was subjected to Preformulation studies, based on the results obtained Dexlansoprazole controlled release tablets were successfully formulated. Formulations prepared by direct compression technique. Set of trials were formulated for which Dexlansoprazole evaluated parameters (bulk density, tapped density, compressibility index, hausner’s ratio, weight, thickness, hardness) were found to lie within the specifications. Dissolution study was performed in USP type II apparatus at 100 RPM in pH 6.8 phosphate buffer. From the results of the in vitro study, it appears that the release of the Dexlansoprazole was significantly influenced by the characteristics of the polymer used.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.